Wang Minghan. Metabolic Syndrome Underlying Mechanisms and Drug Therapies

New Jersey: John Wiley & Sons, Inc., 2011-508 р.This book provides a comprehensive overview of the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development. The authors examine the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome. The development of drug therapies for these diseases and complications is extensively covered. The book offers a comprehensive and in-depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism-based drug discovery and clinical implications.The Physiology of Metabolic Tissues Under Normal and Disease States
Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism
Central Glucose Sensing and Control of Food Intake and Energy Homeostasis
Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus
Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae
Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production
and Lipid Synthesis
Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance
Metabolic Diseases and Current Therapies
Mechanisms and Complications of Metabolic Syndrome
Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL
Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery
Current Antidiabetic Therapies and Mechanisms
Drug Targets for Antidiabetic Therapies
GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes
Sodium Glucose Cotransporter 2 Inhibitors
Fibroblast Growth Factor 21 as a Novel Metabolic Regulator
Sirtuins as Potential Drug Targets for Metabolic Diseases
11b-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes
Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade
Lessons Learned and Future Outlook
Drug Development for Metabolic Diseases: Past, Present and Future